Clik here to view.
Proof-of-Concept for Bedside Rapid Genotyping Test of CYP2C19
A new point-of-care test can rapidly identify people with a common genetic variant associated with impaired clopidogrel function. The authors claim that this is the first study to demonstrate the...
View ArticleClik here to view.
Failure of Another Trial Testing Guided Antiplatelet Therapy Prompts Debate
Updated, Saturday, April 7 Yet another trial has failed to prove the hypothesis that guided antiplatelet therapy with platelet function testing or genetic testing improves outcomes. Although there has...
View ArticleClik here to view.
FDA Approves Generic Clopidogrels As Plavix Loses Patent Protection
For the second time in the past six months, a cardiology mainstay drug has lost patent protection and gone generic. Today the FDA announced that it had approved several generic versions of clopidogrel...
View ArticleClik here to view.
Ticagrelor Joins Clopidogrel And Prasugrel In Updated NSTEMI Guidelines
Ticagrelor (Brilinta, AstraZeneca) gains equal standing with prasugrel (Effient, Lilly) and clopdiogrel in the newly released focused update of the ACCF/AHA guidelines for unstable angina and...
View ArticleClik here to view.
TRILOGY At ESC: No Advantage For Prasugrel Over Clopidogrel In Medical ACS...
The newer antiplatelet agent prasugrel was no better than the old standby clopidogrel for treating patients with acute coronary syndrome (ACS) who are not undergoing revascularization. The results of...
View ArticleClik here to view.
Danish Survey Finds Clopidogrel Less Effective In Diabetics
A large nationwide survey of MI survivors in Denmark provides new information about the efficacy of antiplatelet therapy with clopdiogrel in patients with diabetes. In a paper published in JAMA,...
View ArticleClik here to view.
Early Results: Antiplatelet Drug Cangrelor Appears Effective For PCI
The experimental antiplatelet drug cangrelor was superior to traditional clopidogrel in reducing ischemic events at 48 hours in PCI patients, according to the Medicines Company, which is developing the...
View ArticleClik here to view.
Cangrelor During PCI May Reduce Ischemic Events
In the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) trial, the intravenous platelet inhibitor cangrelor was tested for its effect on...
View ArticleClik here to view.
Some Patients With Minor Stroke Or TIA May Benefit From Early Clopidogrel And...
Some people with minor ischemic stroke or transit ischemic attack (TIA) may benefit from dual antiplatelet therapy with aspirin and clopidogrel, according to a large new study from China published in...
View ArticleClik here to view.
FDA Advisory Panel Recommends Against Approval Of Cangrelor
The FDA’s Cardiovascular and Renal Drugs Advisory Committee today recommended against the approval of cangrelor, the investigational new antiplatelet drug from the Medicines Company. In a 7-2 vote the...
View ArticleClik here to view.
Prescription Delay Following Stent Implantation Is a Common and Deadly Problem
After receiving a stent, many patients delay or fail to fill their prescription for clopidogrel or another antiplatelet agent. Now, a study published in the Journal of the American Heart Association...
View ArticleTicagrelor No Better Than Clopidogrel In Peripheral Artery Disease
AstraZeneca announces top-line results from EUCLID trial ahead of the AHA. Ticagrelor is no better than clopidogrel in patients who have peripheral artery disease, a large new study will show. On...
View Article
